Dr. Daley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1400 Jackson St
Denver, CO 80206Phone+1 303-388-4461Fax+1 303-270-2206
Education & Training
- University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 1994 - 1997
- University of California (San Francisco)Residency, Internal Medicine, 1983 - 1987
- University of Mississippi School of MedicineClass of 1983
Certifications & Licensure
- CO State Medical License 2004 - 2025
- CA State Medical License 1985 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Top Doctors Castle Connolly, 2013-2022
- Top Doc US News and World Report, 2012-2017
- World Lung Health Award American Thoracic Society, 2016
- Join now to see all
Clinical Trials
- Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria Start of enrollment: 2012 Apr 19
- Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Start of enrollment: 2017 Apr 11
- Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough Start of enrollment: 2022 Oct 03
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- In vitro susceptibility of 147 international clinical Mycobacterium abscessus isolates to epetraborole and comparators by broth microdilution.Minh-Vu H Nguyen, Vinicius Calado Nogueira de Moura, Tiffany R Keepers, Jakko van Ingen, Charles L Daley
The Journal of Antimicrobial Chemotherapy. 2024-12-31 - Durlobactam in combination with β-lactams to combat.Eunjeong Shin, Khalid M Dousa, Magdalena A Taracila, Christopher R Bethel, Mary Nantongo
Antimicrobial Agents and Chemotherapy. 2024-12-23 - Executive Summary: State-of-the-Art Review: Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects.Minh-Vu H Nguyen, Michelle K Haas, Shannon H Kasperbauer, Vinicius Calado Nogueira de Moura, Jared J Eddy
Clinical Infectious Diseases. 2024-10-15
Journal Articles
- Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in BronchiectasisMark L Metersky, Charles L Daley, The New England Journal of Medicine
Lectures
- The Denver TB CourseNational Jewish Health, Denver, Colorado - 4/10/2013
- 3rd Symposium on IGRAsUniversity of California San Diego, Waikoloa, Hawaii - 1/12/2012
Other
- Epidemiology, clinical manifestations, and diagnosis of osteomyelitis due to nontuberculous mycobacteriaDaley CL, Kasperbauer S
http://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-osteomyelitis
UpToDate, Wolters Kluwer Health - 2012-11-27 - Treatment of osteomyelitis due to nontuberculous mycobacteria in adultsDaley CL, Kasperbauer S
http://www.uptodate.com/contents/treatment-of-osteomyelitis-due-to-nontuberculous-mycobacteria-in-ad
UpToDate, Wolters Kluwer Health - 2012-11-27
Press Mentions
- A Modified BPaL Regimen for Tuberculosis Treatment Replaces Linezolid with Inhaled SpectinamidesOctober 8th, 2024
- National Jewish Health Develops Antibiogram to Help Providers Treat Nontuberculous MycobacteriaFebruary 2nd, 2023
- What Happened to Spice? Dangers of Plastic Surgery in the DRNovember 16th, 2022
- Join now to see all
Professional Memberships
- Member
- ChestFellow
- Infectious Diseases Society of AmericaMember
- International Union Against Tuberculosis and Lung DiseaseMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: